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Induction of labour with titrated oral Misoprostol suspension. A 
comparative study with vaginal Misoprostol
P ZVANDASARA, G SAUNGWEME, J MLAMBO, W CHIDEMBO, N MADZIVANZIRA, C MWANJ1RA
%
Abstract
Objective: To compare the effectiveness of titrated orally and vaginally administered misoprostol for 
induction of labour.
Study Design: Unmasked randomized controlled trial.
Setting: Department of Obstetrics and Gynaecology University of Zimbabwe, Harare.
Subjects: Pregnant women with singleton foetus in cephalic presentation booked for induction of labour, 
were randomized to receive titrated orally or vaginally administered misoprostol.
Main Outcome Measures: The main outcomes were the duration of labour and induction to delivery interval.
The secondary outcomes were neonatal and maternal complications.
Methods: 134 women were recruited into the study; 69 and 65 were randomized into orally and vaginally 
administered misoprostol respectively.
Results: The baseline characteristics in the two groups were similar. Women induced with titrated oral 
misoprostol suspension had a shorter interval from administration of the drug to initiation of uterine 
contractions (OR = 0.94 .95% Cl 0.42 to 2.12 ) and a longer duration of labour (OR = 0.36; 95% Cl 0.16 to 
0.79). Labour was augmented with oxytocin in the oral group. The mean drug dose was 28mcg in the oral 
group.
There was no difference in the mode of delivery between the two groups. Hypertonic uterine contractions 
were not detected. Ruptured uterus did not occur in the study population. There were more neonatal 
admissions in the vaginal than the oral group (OR = 1.03 .95% Cl 0.29 to 1.39).
Conclusion: Titrated oral misoprostol suspension is as effective and safe as vaginal misoprostol for induction 
of labour even in poor resource countries where intrapartum monitoring is inadequate.
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Induction to delivery interval o f midtrimester 
pregnancy with an intra-uterine death can be as short as 
30 minutes inclusive of complete delivery of the 
placenta.3
Although misoprostol is not licenced for induction of 
labour, its use in poor resource countries has increased 
in the past 10 years because it is cheap, available, has a 
long half life and can be stored at room temperature.5
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Introduction
Misoprostol (cytotec) a synthetic prostaglandin £, 
analogue has antisecretory and protective properties 
which promote healing of gastric/duodenal ulcers.1 It 
has uterotonic effect on the uterus which has spured its 
use in the treatment of post partum haemorrhage, 
termination of pregnancy and induction of labour.2-4
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Randomized trials have shown misoprostol to be better 
or equivalent to prostaglandin E2 in inducing labour.610 
Induction of labour with vaginal misoprostol was 
associated with shorter duration of labour.610 
In a study at Harare Hospital Zimbabwe, intravaginal 
misoprostol was the best agent for cervical priming and 
induction of labour with 63% of women going into 
labour after a single dose.6,10 The duration of labour was 
significantly shorter; there was less use of oxytocin in 
labour, a shorter induction to delivery interval, and 
fewer Caesarean sections for failure to progress.6,10
Concerns of increased maternal and foetal morbidity 
have been documented with the use of vaginal 
misoprostol." Hypertonic uterine contractions; 
ruptured uterus; tachysystole; fever; chorioamionitis 
and vaginal pain have been described.7'" Ruptured 
uterus in primiparous women has been documented 
when lOOmpg was use3.12 Other minor side effects in 
the mother were nausea; vomiting; diarrhea; rashes; 
dizziness; abdominal pains and flatulence.1,11 Passage 
of meconium, low Apgar scores and increased 
Caesarean section for foetal heart rate abnormalities 
have been observed in the foetus.7
The optimal route and safe dosage of misoprostol is 
still being studied. Misoprostol tablets can be given 
intra-vaginally, sublingually, rectally and orally as a 
suspension.2,13 Most studies in the literature have used 
the intravaginal route.3,5,6 The side effects of vaginal 
misoprostol are dose related.12 The current drug 
formulation of two hundred microgram 200pg tablet 
available in our country is difficult to break into a 
measurable dose.13 The absorption of misoprostol in the 
vagina is slow and erratic making it difficult to estimate 
the drug levels before a repeat dose is inserted. Arepeat 
dose creates an accumulation of the drug leading to 
overdose. Once the drug is dissolved in the vagina it 
cannot be removed if foetal or maternal complications 
occur.
When a 200pg misoprostol tablet is dissolved in 
200ml of water each 1ml contains lug, a known drug 
dose can be administered. Small incremental doses 
reduce hyperstimulation making it safer to use in 
multiparous women.12 The drug can be stopped 
immediately when maternal and foetal complications 
develop.
Pharmacokinetic studies have shown a more rapid 
time to peak concentration and rapid onset of uterine 
activity with misoprostol administered orally rather 
than vaginally14. The induction to delivery time and 
failed vaginal delivery in 24 hours was less with the 
vaginal than with oral route.15'17 Vaginal misoprostol 
when compared to an equivalent oral dose results in 
sustained uterine activity.18
Studies which have compared oral and vaginal 
misoprostol have used fixed oral dose regiments.14,19 
One multicentre study compared titrated oral 
misoprostol suspension with vaginal dinoprostone.13
This study was carried out in a poor resource country 
where the effectiveness and safety of oral suspension
was com pared with vaginally  adm inistered 
misoprostol in induction of labour. It was hypothesized 
that misoprostol given orally in decreasing doses 
reduces the risk of uterine hyperstimulation, uterine 
rupture and foetal heart rate abnormalities.
Materials and Methods
Between January 2005 to June 2008 all suitable 
pregnant women admitted to Harare Maternity 
Hospital; Zimbabwe, for induction of labour were 
recruited into the study. The indications, timing of 
induction and management of the women were 
determined by the obstetric team in the labour ward on 
that day. Singleton pregnancies with a live foetus in a 
cephalic presentation were included in the study as well 
as those with an intra-uterine death. The patients signed 
an informed consent form. Excluded were women 
with an abnormal foetal heart, cephalopelvic 
disproportion, previous Caesarean section, multiple 
pregnancy or known sensitivity to misoprostol. All the 
women had an assessment of the Bishop score before 
the drugs were administered.
The study was approved by the hospital ethics 
committee. Eligible women were randomly allocated 
to oral or vaginal misoprostol. Investigators were not 
blinded as the drug was given as an oral suspension or 
as a tablet inserted into the vagina. Randomisation of 
the subjects in equal numbers was done using a table of 
random numbers, allocated into groups recorded onto 
cards placed in an opaque envelope, 
sequentially numbered and placed into a box. The time 
of administration of the drugs was recorded.
In the women randomised to the oral group, 200mpg 
tablet was dissolved in 200ml of safe water by stirring 
until small sediments remained. Each 1ml contained 
approximately lpg of Misoprostol. An ordinary 
marked 20ml syringe was used to draw the suspension. 
The suspension was given to the patient to swallow in 
the presence of the midwives. The starting dose for 
primiparous was 30ml followed by 20 ml every hour 
until uterine contractions started. Parous women were 
given 20 ml) to start dose followed by 15ml every hour 
until uterine contractions started. In a patient where the 
whole 200ml was given without any contractions, 
alternative methods of induction or delivery of the baby 
were initiated.
In the other group, 200|ag misoprostol tablet was 
broken into a quarter tablet (approximately 50pg) was 
inserted into the posterior vaginal fornix by the 
attending doctors.
Patients were monitored throughout labour, delivery 
and post natally until discharged. During labour the 
membranes were ruptured when the cervix was 3 cm 
dilated except in HIV positive where they were 
ruptured at full cervical dilation.
The management of the patients during labour and 
post partum was done by the team of doctors 
responsible for the patient including those on call. The 
interval from administration of misoprostol to the start
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of uterine contractions and delivery was recorded. The 
progress of labour was plotted on a partogram (labour 
chart.) The foetal heart rate, cervical dilation, descend 
of the presenting part, passage of meconium, strength 
and duration of contractions, blood pressure, 
temperature, and urine output were monitored.
Hypertonic uterine contractions defined as 
contractions lasting two minutes were specifically 
looked for. Biochemical tests were performed where it 
was necessary. Labour was augmented with oxytocin 
where necessary four hours after stopping oral or 
vaginal misoprostol. Pethidine was administered by the 
midwives. Caesarean sections were done where 
indicated. In all patients, blood loss in the third stage 
was estimated and recorded.
The main outcome measures of the study were the 
duration of labour and the induction to delivery 
interval. Secondary'measures in the mother were post
partum haemorrhage, vaginal pain and hypertonic 
uterine contractions. Passage of meconium, admission 
to neonatal unit, low Apgar score and death of the 
neonate in the first week were the primary outcomes of 
the foetus.
To detect for a four hour difference in the mean 
duration of labour, at a 5% significance level and a 
power of 90%, the minimum sample size was estimated 
at 60 per group. We enrolled a total of 134 women, 69 in 
oral and 65 in the vaginal group.
Results
A total of 134 women were recruited into the study; 69 
(51 %) were induced with oral suspension and 65 (49%) 
with vaginal misoprostol.
Table I: Baseline characteristics o f  women induced with oral Misoprostol and vaginal Misoprostol.
Characterstics Oral (%) Vaginal (%) p value
Number 69 (51) 65 (49)
Median age (years) 23 24 0.21
Median gestational age (weeks) 38 38 0.56
Median parity 0 1 0.27
Median bishop score 5 5 0.09
Traction catheter used 3 0 0.19
Indication for induction
Hypertension 22 (32) 21 (32)
Post term 38 (55) 37 (58) 0.36
Prelabour rupture membranes 8(11) 4 (5)
Intra-urine death 1 (1) 3 (5)
Time of membrane rupture Odd Ratio (95% Cl)
Prelabour 7(10) 4 (7) 0.87 (0.48 - 3.58)
During labour 39 (57) 32 (49) 1.5 (1.2-1.8)
At delivery 23 (23) 29(44) 1.01 (0.36- 1.07)
There were no differences between the two groups in 
age, parity, mean gestational age and median bishop 
score.
The indications for induction in both groups were 
intra-uterine death, hypertension, post term and
prelabour ruptured membranes. Traction catheter 
was used in 3% of the women in the oral group, none 
in the vaginal group.
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Table II: Labour characteristics o f  women induced with oral vaginal Misoprostol.
C haracterstics O ral n (% ) V aginal n (% ) O R  (95%  C l)
Number 69(100) 65 (TOO)
D oses given  to in itia te lab ou r : m eg
20 56 (82) 0
30 1 0 ) 0
50 3 (4) 62 (95) 1.48 (0.46- 1.55)
Greater than 50 9 (13) 3 ( 5)
Mean number of doses given 5 2
Mean drug dose meg 28 50
Interval betw een  adm in istration  o f  dru gs to begin n in g  contraction: hrs
Less than 10 17 (25) 9(13) 0.94 (0.42-2.12)
10 to 15 43 (63) 38 (58) 1.01 (0.65-1.57)
Greater than 15 9(12) 19 (29) 1.06 (0.5-2.3)
Mean duration of labour 10.3 6.8 0.94(0.4-1.3)
A ugm entation  lab ou r w ith  oxytocin
Yes 14(21) 1 (2) p=0.06
Table II illustrates the labour characteristics of the a shorter time interval from administration of the drug 
women in the study; 2pg of oral misoprostol to the beginning of uterine contraction: 25% in the oral
suspension was sufficient to initiate labour :in 95% group and 13% in the vaginal group had stated
women, mostly parous women. A small proportion, 1% contractions in less than 10 hours. The difference was 
and 4%, required up to 30mcg and 50mug respectively. statistically significant (OR 0.94 ;95% Cl 0.42 to 2.12). 
Thirteen percent required more than 50ug of oral The mean duration of labour was longer in women 
misoprostol, all nulliparous women. A quarter tablet administered oral misoprostol than vaginal, 10.3 hours 
initiated labour in 95% of women in the vaginal group and 6.8 hours respectively. Labour was augmented 
whilst 5% required a second dose. The mean drug dose with oxytocin in 21 % of women in the oral and 1 % in
given in the oral group was 28pg. the vaginal group.
Women who were induced with oral misoprostol had
Table III: Outcome o f induction o f labour using oral and vaginal Misoprostol.
C haracteristic O ral (% ) V aginal (% ) p value
Number 69 (100) 65 (100)
Normal vaginal delivery 61 (89) 59 (90) 0.7
Vacuum extraction/Forceps 3 (4) 3 (5) 0.09
Emergency Caesarean section 5 (7) 3 (5) 0.12
Indications for C aesarean  section 5 (100) 3 (100)
Failure to progress 4 (80) 1 (33) 0.08
Cord prolapse 0 1 (33) 0.02
Cephalopelvic disproportion 0 1 (34)
Malpresentation 1 (20) 0 0.01
C om plications o f  induction
None 63 (92) 69 (90)
Post partum haemorrhage 5 (7) 5 (8) 0.15
Vomiting 1 (1) 1 (1) 0.03
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Table III illustrates the outcome of induction of labour 
using oral and vaginal misoprostol: 89% and 90% of 
women induced with oral and vaginal misoprostol had 
successful normal vaginal deliveries respectively.
A small proportion in both groups had vacuum 
extraction. Caesarean sections were performed in 7% 
and 5% in the oral and vaginal groups respectively. 
The differences in the mode of deliveries did not reach 
statistical significance.
The indications for caesarean sections were failure to
progress, cord prolapse, cephalopelvic disproportion 
and malpresentation. There were no operations 
perform ed on account o f foetal heart rate 
abnormalities.
The complications recorded in both groups were 
vomiting and post partum haemorrhage. The difference 
was not significant. There were no patients who either 
ruptured their uterus or had hypertonic uterine 
contractions. No women died during the study.
Table IV: Foetal outcome following induction with oral and vaginal misoprostol.
Characteristics Oral n (%) Vaginal n (%) OR (95% Cl)
Number „ 69 (100) 65(100)
Live birth 68 (99) 62 (97) 0.9
Still birth 1 0 ) 3 (3)
Mean birth weight (grams) 2929 2971 p=0.62
Mean Apgar score 8.4 8.2 1.01(0.9-2.6)
Neonatal unit admission
Yes 11 (17) 15 (28)
Reasons for admission to neonatal unit 11 (100) 15(100)
Low Apgar score 0 1 (6)
Meconium passage 6(55) 8(54) 1.07 (0.9-2.8)
Prolonged labour 1 (9) 0
Recessing 0 3(20)
Prelabour rapture of membranes 4(36) 3 (20) 1.13 (0.25 -2.05)
Table IV illustrates the foetal outcome following 
induction of labour with oral and vaginal misoprostol. 
Ninety percent of the babies in the oral and 97% in the 
vaginal group were delivered alive and well. The still 
bom babies in both groups were known intra uterine 
deaths and were the reason why induction was done. 
There were no intrapartum or first week neonatal 
deaths in both groups.
The mean birth weight and Apgar scores were similar 
in both groups, 28% of babies in the vaginal group and 
17% in the oral group were admitted into the neonatal 
unit; all survived. The difference was statistically 
significant (OR 1.03 ; 95% Cl 0.29 to 1.38). Meconium 
passage; prelabour rapture of membranes; low Apgar 
score; prolonged labour and chest recession were the 
main reasons for admission to the neonatal unit.
Discussion
This was an unmasked randomized controlled study in 
which the midwives knew what was being given to the 
patient. The drags were administered as suspension or 
tablets orally and vaginally respectively and could not 
be masked. We feel, however, that our study results 
were not biased by this as data entry was done by
midwives not involved in the management of the 
patients.
We compared oral and vaginal misoprostol for 
induction of labour because the hospital or the patients 
could not afford to purchase prostaglandins E2. One 
multicentre study compared oral misoprostol with 
vaginal dinoprostone.13
In another study, oral and vaginal misoprostol were 
compared with prostaglandin gel and pessaries. At our 
institution, a quarter tablet of misoprostol inserted 
vaginally has been adopted for induction of labour 
without any study to support it. Both oral and vaginally 
adm inistered m isoprostol are cheaper than 
dinoprostone.1
Oral administration was easy and accepted by patients 
whilst discomfort was felt by some patients on vaginal 
insertion. Latex gloves worn by the doctors made the 
vaginal route more expensive than the oral.
A starting oral dose of 30mug in primiparous and 
20mpg in multiparous women were chosen as 20 to 
25mug is thought to be the optimum dose to prime and 
ripen the cervix and stimulate uterine contractions.13 
Our dosing schedule was different from other 
researchers who gave the oral drag every two hours 
until there were adequate contractions occurred.13 The
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mean oral dose was 28mug in our study.
Our study showed that oral titrated misoprostol 
suspension was associated with a shorter interval from 
induction to initiating uterine contractions. The 
duration of labour was longer and primiparous women 
required augmentation of labour with oxytocin. 
Multiparous women required only 20mcg oral 
misoprostol to initiate labour and labour was much 
shorter when compared with women of lower parity. 
Primiparous women, a fifth of the study population 
required augmentation of labour with oxytocin.
The mode of delivery was similar in the two groups. 
The Caesarean section rate in the study was much 
lower than the hospital's monthly average of 20%.2U 
Hypertonic uterine contractions were not detected by 
the midwives, who identified uterine the contractions 
by palpation of the ^abdomen. We did not have 
continous cardiotocography or external manometry 
which has been used by other researchers. Four percent 
of patients given misoprostol orally developed uterine 
hyperstimulation with fetal heart rate changes in a 
multicenter study.11 A study done at our institution 
failed to identify hyperstimulation; this was attributed 
to poor monitoring of the uterine contractions during 
labour.6'8
The interval from administration of the drug to 
initiation of uterine contractions was short in both 
groups. Patients with prelabour rupture of membranes 
had a shorter duration of labour. This suggests that 
misoprostol acts faster on an already primed cervix as 
is the case in women with prelabour rupture of 
membranes. Oral administration of misoprostol is 
preferable to vaginal when inducing women with 
prelabour rupture of membranes as it reduces the risk of 
introducing infection. The tablet inserted in the vagina 
can be washed away before it has dissolved in women 
with prelabour rupture of membranes.
We are of the opinion that the route and dose of 
misoprostol used in our study reduced the risk of 
uterine hyperstimulation. The disadvantage of oral 
misoprostol in this study was the longer duration of 
labour and the need for augmentation of labour with 
oxytocin. However, this was compensated by 
successful vaginal delivery; reduced risk of uterine 
hyperstimulation; short interval from administration of 
the drug to initiation of labour and fewer admissions to 
neonatal unit.
The rate of foetal distress was low in our study 
although some studies have shown higher rates.7 There 
was less meconium passage associated with oral 
misoprostol attributed to the small titrated doses.
Conclusion
Titrated oral misoprostol is as safe and effective as 
vaginal misoprostol for induction of labour in poor 
resource countries where monitoring of labour is 
minimal. Although the study was done at a tertiary 
hospital, the protocols in our district hospital labour 
wards are similar, the drug can be used at district and
provincial hospitals.
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